Why Investors Should Care About MindMed’s LSD Trial for Anxiety
MindMed will present preliminary results from a Phase 2a study treating Generalized Anxiety Disorder with LSD therapy next month.
James Hallifax is an entrepreneur who co-founded The Psychedelic Investor, a media company focused on investing in psychedelic medicines which treat mental health conditions. Together with his business partner, they have grown their YouTube Channel to be the largest Channel dedicated to Investing in Psychedelics. Through their partnership with Psychedelic Spotlight, James aims to help educate retail investors on the potential for substances like LSD, MDMA and Magic Mushrooms to heal, and for early investors who make the right choices to make a lot of money. Rather than focus on day to day stock movements, James follows the underlying science of the industry, to help people understand which companies are the most likely to succeed long term.
MindMed will present preliminary results from a Phase 2a study treating Generalized Anxiety Disorder with LSD therapy next month.
This deal will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
The electric pulses could be organized into “trains” that resemble human words, and a vocabulary of “up to 50 words” appears to be present.
Interested in participating in a psychedelic study? Here’s an in-depth walk through guide so you can take actionable steps to make it happen.
Here’s why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
NeonMind finds that its proprietary psilocybin has the ability to target visceral fat, effectively reducing weight gain in obese subjects.
PharmaTher evaluates safety, tolerability and efficacy of low-dose ketamine infusion for treatment of LID in Parkinson’s Disease patients.
Core One Labs appears to be following in footsteps of Mind Cure, but that doesn’t mean the entire psychedelics industry is in trouble.
Our resident Psychedelic Investor James Hallifax looks at the pros and cons of this Canadian-based company developing DMT for therapeutic use.
Anyone who has ever suffered from an eating disorder, such as anorexia or bulimia, knows that beating the mind virus is a constant struggle. While therapy can help some, for many, the situation can seem hopeless. But it need not be. Now, a new tool is coming into focus that may be able to help […]
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.